The Orphan Drug Act provided what to pharmaceutical manufacturers?

• A. Economic and tax incentives for developing drugs for rare diseases
• B. Expedited approval for all drugs
• C. Universal labeling requirements
• D. Prohibition of false claims

Answer: (A)

The Orphan Drug Act is about encouraging development of treatments for rare diseases by providing financial incentives to drug manufacturers. Its main tools are economic boosts like tax credits for clinical research, seven-year market exclusivity when a drug is approved for an orphan indication, and sometimes waivers or reductions of FDA fees. These incentives help offset the small patient populations and higher costs that make it hard to profit from rare-disease drugs, spurring more research and eventual approvals. It isn’t about expedited approval for all drugs, universal labeling requirements, or prohibiting false claims; those areas are handled by separate regulatory provisions and laws.